The Muscle Phenotyping and Imagine Core is designed to enable muscle and non-muscle researchers alike to access a variety of assessment tools for the study of muscle phenotypes. The Core will be useful in 3 main ways. First, the Core will provide a means for investigators to test lead therapeutic compounds in mice to evaluate their effect on muscle pathology. Drugs that delay the onset of disease or reduce muscle pathology will be identified through the small molecule high-throughput screen (Core B) or can be investigator initiated. For these assessments, both traditional (histology, muscle function tests) and non-traditional (optical imaging, MRI) methods will be available for researchers to utilize on a fee for service basis. Second, because most muscular dystrophies involve changes in the dystrophin-glycoprotein complex, biochemical assessments of muscular dystrophy-related proteins will be an additional service offered by this core. Finally, as more and more researchers are making use of transgenic mouse technology, it has become necessary for these individuals to explore muscle phenotypes in their novel knock out and transgenic animals. Since these researchers lack the necessary experience to assess muscle tissue, this Core will provide access to resources, expertise and training necessary to allow them to explore muscle morphology and function in a manner that would not otherwise be available to them.
The Aims of the Core are:
Aim 1 : To enable researchers the opportunity, resources and training to evaluate muscle phenotypes in transgenic mice;
Aim 2 : To enable researchers the opportunity, resources and training to evaluate the efficacy of pharmacological compounds on muscular dystrophy pathogenesis, using quantitative functional and histological outcome measures as well as state-of-the art imaging technologies;
Aim 3 : To enable researchers the opportunity, resources and training to evaluate biochemical outcomes following treatments with pharmacological compounds.
This core facility will be a valuable resource to Center Investigators as well as to the greater dystrophy community by facilitating rapid, pre-clinical testing of compounds. The most promising drugs identified through these combined efforts will be taken to human clinical trials.
|DiFranco, Marino; Kramerova, Irina; Vergara, Julio L et al. (2016) Attenuated Ca(2+) release in a mouse model of limb girdle muscular dystrophy 2A. Skelet Muscle 6:11|
|Reyhan, Meral L; Wang, Zhe; Kim, Hyun J et al. (2016) Effect of free-breathing on left ventricular rotational mechanics in healthy subjects and patients with duchenne muscular dystrophy. Magn Reson Med :|
|Capote, Joana; Kramerova, Irina; Martinez, Leonel et al. (2016) Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype. J Cell Biol 213:275-88|
|Srinivasan, Subashini; Kroeker, Randall M; Gabriel, Simon et al. (2016) Free-breathing variable flip angle balanced SSFP cardiac cine imaging with reduced SAR at 3T. Magn Reson Med 76:1210-6|
|Brown, Robert; Lee, Hane; Eskin, Ascia et al. (2016) Leveraging ancestry to improve causal variant identification in exome sequencing for monogenic disorders. Eur J Hum Genet 24:113-9|
|Young, Courtney S; Hicks, Michael R; Ermolova, Natalia V et al. (2016) A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell 18:533-40|
|Kramerova, Irina; Ermolova, Natalia; Eskin, Ascia et al. (2016) Failure to up-regulate transcription of genes necessary for muscle adaptation underlies limb girdle muscular dystrophy 2A (calpainopathy). Hum Mol Genet 25:2194-2207|
|Gibbs, Elizabeth M; Marshall, Jamie L; Ma, Eva et al. (2016) High levels of sarcospan are well tolerated and act as a sarcolemmal stabilizer to address skeletal muscle and pulmonary dysfunction in DMD. Hum Mol Genet :|
|Mokhonova, Ekaterina I; Avliyakulov, Nuraly K; Kramerova, Irina et al. (2015) The E3 ubiquitin ligase TRIM32 regulates myoblast proliferation by controlling turnover of NDRG2. Hum Mol Genet 24:2873-83|
|Arboleda, Valerie A; Lee, Hane; Dorrani, Naghmeh et al. (2015) De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay. Am J Hum Genet 96:498-506|
Showing the most recent 10 out of 48 publications